Immune Design Corp. (NASDAQ:IMDZ) shares were down 2.7% during trading on Monday . The stock traded as low as $7.81 and last traded at $7.95, with a volume of 61,839 shares. The stock had previously closed at $8.17.

Several research analysts have recently commented on IMDZ shares. Leerink Swann restated a “buy” rating on shares of Immune Design Corp. in a research note on Thursday, May 12th. Wells Fargo & Co. restated a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Jefferies Group restated a “buy” rating and set a $20.00 price target on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Cowen and Company restated a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Finally, Zacks Investment Research lowered shares of Immune Design Corp. from a “buy” rating to a “hold” rating in a research note on Friday, May 13th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Immune Design Corp. currently has an average rating of “Buy” and a consensus price target of $24.00.

The stock’s market cap is $157.80 million. The stock’s 50-day moving average price is $10.22 and its 200-day moving average price is $12.11.

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.01. Equities research analysts anticipate that Immune Design Corp. will post ($2.70) earnings per share for the current fiscal year.

A number of hedge funds have bought and sold shares of IMDZ. Jennison Associates LLC increased its stake in Immune Design Corp. by 0.4% in the fourth quarter. Jennison Associates LLC now owns 203,452 shares of the company’s stock valued at $4,085,000 after buying an additional 769 shares during the last quarter. Jennison Associates increased its stake in Immune Design Corp. by 0.6% in the third quarter. Jennison Associates now owns 202,683 shares of the company’s stock valued at $2,473,000 after buying an additional 1,224 shares during the last quarter. Finally, Oxford Asset Management acquired a new stake in Immune Design Corp. during the fourth quarter valued at about $1,166,000.

Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.